McKesson Corp. acquires 70% stake in Core Ventures, a Florida Cancer Specialists subsidiary, for $2.49bn.

McKesson Corp., a pharmaceutical distribution company, has agreed to acquire a 70% stake in Core Ventures, a subsidiary of Florida Cancer Specialists & Research Institute, for approximately $2.49bn. This follows McKesson's strategic focus on community-based oncology services, and enables the company to diversify its specialty services. Florida Cancer Specialists will retain a minority interest in Core Ventures, and continue to operate independently. Core Ventures, which provides administrative support services to FCS clinics across Florida, will join McKesson's US Oncology network.

August 26, 2024
50 Articles